Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder

This study has been completed.
Information provided by:
Eli Lilly and Company Identifier:
First received: July 19, 2004
Last updated: July 21, 2006
Last verified: July 2006